Cancer cells undergo accelerated evolutionary changes; thus, under the pressure of novel generations of EGFR TKIs, we should expect to see new mechanisms of resistance.
Arkadiusz Z. Dudek, MD, PhD
Advertisement
Articles by Arkadiusz Z. Dudek, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
3
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
4
Experts Analyze 6-Year Zanubrutinib Data Across CLL/SLL Settings
5